Publications by authors named "Toby Talbot"

Claim this Profile
B
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
Solange Peters, Christian Schulz, Martin Reck, Kumar Prabhash, Dariusz Kowalski, Toby Talbot

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study).
Siow Ming Lee, Christian Schulz, Anne-Marie Baird, Kumar Prabhash, Dariusz Kowalski, Toby Talbot

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Igor Gomez-Randulfe, Sofía Silva Díaz, Carles Escriu, Saara Mohammed, Riyaz Shah, Toby Talbot

Ther Adv Med Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Siow Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Toby Talbot

Lancet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.
Natalie M Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Toby Talbot

Immunother Adv· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab.
Michael Rowe, Leonie Eastlake, Timothy Norris, Timothy Farley, Toby Talbot

J Immunother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, Toby Talbot

Ann Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Toby Talbot, Adam Dangoor, Riyaz Shah, Jay Naik, Denis Talbot

Lung Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Saif S Ahmad, Wendi Qian, Sarah Ellis, Elaine Mason, Muhammad A Khattak, Toby Talbot

Melanoma Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis